	US 11,883,562 B2
	Hydrogels based on blood plasma components, process and uses thereof
João Filipe Colardelle Da Luz Mano, Aveiro (PT); Catarina De Almeida Custódio, Aveiro (PT); and Sara Catarina Nunes Da Silva Santos, Fornos CPV (PT)
Assigned to UNIVERSIDADE DE AVEIRO, Aveiro (PT)
Appl. No. 16/955,522
Filed by UNIVERSIDADE DE AVEIRO, Aveiro (PT)
PCT Filed Dec. 18, 2018, PCT No. PCT/IB2018/060266 § 371(c)(1), (2) Date Jun. 18, 2020, PCT Pub. No. WO2019/123259, PCT Pub. Date Jun. 27, 2019.
Claims priority of application No. 110463 (PT), filed on Dec. 18, 2017.
Prior Publication US 2020/0316261 A1, Oct. 8, 2020
Int. Cl. A61L 27/52 (2006.01); A61L 27/10 (2006.01); A61L 27/12 (2006.01); A61L 27/26 (2006.01); A61L 27/36 (2006.01); A61L 27/38 (2006.01); A61L 27/56 (2006.01); C12M 1/12 (2006.01)

CPC A61L 27/52 (2013.01) [A61L 27/10 (2013.01); A61L 27/12 (2013.01); A61L 27/26 (2013.01); A61L 27/3616 (2013.01); A61L 27/3834 (2013.01); A61L 27/56 (2013.01); C12M 25/00 (2013.01); A61L 2300/414 (2013.01); A61L 2400/06 (2013.01)]

15 Claims

1. A hydrogel, comprising

a human platelet lysate,

wherein the human platelet lysate is modified to be directly linked to at least one polymerizable moiety, wherein the at least one polymerizable moiety is a methacrylate;

wherein the human platelet lysate has a concentration of 10-20% w_{human platelet lysate}/V_hydrogel; and

wherein the degree of substitution ranges between 14-25% of modified peptides per number of total peptides in the human platelet lysate.